Reunion Neuroscience (TSE:REUN) Stock Rating Reaffirmed by HC Wainwright

Reunion Neuroscience (TSE:REUNGet Rating)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday. They presently have a C$20.00 target price on the stock.

Separately, Roth Capital initiated coverage on Reunion Neuroscience in a research report on Friday, December 16th. They set a “buy” rating and a C$11.00 target price on the stock.

Reunion Neuroscience Stock Performance

Shares of TSE:REUN opened at C$1.77 on Thursday. Reunion Neuroscience has a 52-week low of C$1.08 and a 52-week high of C$13.10.

About Reunion Neuroscience

(Get Rating)

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.

Recommended Stories

Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.